Cardiology

Original Research

Mortality and Reinfarction among Patients Using Different Beta-Blockers for Secondary Prevention after a Myocardial Infarction

Andersen S.S.a · Hansen M.L.a · Gislason G.H.a · Folke F.a · Schramm T.K.a · Fosbøl E.a · Sørensen R.a · Rasmussen S.b · Abildstrøm S.Z.a · Madsen M.c · Køber L.d · Torp-Pedersen C.a

Author affiliations

aDepartment of Cardiology, Gentofte University Hospital, Hellerup, and bNational Institute of Public Health, cDepartment of Public Health, University of Copenhagen, and dDepartment of Cardiology, The Heart Centre, Rigshospitalet, Copenhagen, Denmark

Keywords: Myocardial infarctionβ-BlockersDrug treatmentSecondary preventionClinical efficacy

Related Articles for ""
Cardiology 2009;112:144–150
https://doi.org/10.1159/000143389

Log in to MyKarger to check if you already have access to this content.


Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve

  • Unlimited fulltext viewing Of this article
  • Organize, annotate And mark up articles
  • Printing And downloading restrictions apply

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: December 19, 2007
Accepted: January 31, 2008
Published online: July 09, 2008
Issue release date: December 2008

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Abstract

Objectives: To study differences in the clinical efficacy of various brands of β-blocker in secondary prevention after a myocardial infarction (MI). Methods: All patients hospitalized with a first MI between 1995 and 2002 who were still alive 30 days after discharge and had had at least one prescription for a β-blocker filled were identified by individual-level linkage of nationwide registries of hospitalizations and drugs dispensed from pharmacies. A total of 32,259 MI patients were included in the study. Multivariable Cox proportional hazard models were used to analyze the risks of death and recurrent MI related to treatment with different β-blockers. Results: The risks for death and recurrent MI were similar in patients using different β-blockers, except that mortality from all causes among patients with a prescription for sotalol was higher. Subgroup analyses of high-risk patients with diabetes or congestive heart failure and of patients using comparable dosages of β-blockers did not show effects on the risk of death or recurrent MI. Conclusion: Except for sotalol, the different types of β-blocker had similar clinical efficacy in reducing mortality and the recurrence of MI. The equivalent efficacy remained when high-risk patients were analyzed separately.

© 2008 S. Karger AG, Basel



Related Articles:

References

  1. Freemantle N, Cleland J, Young P, Mason J, Harrison J: Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730–1737.
    External Resources
  2. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C: Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341–1362.
    External Resources
  3. The beta-blocker heart attack trial. Beta-Blocker Heart Attack Study Group. JAMA 1981;246:2073–2074.
    External Resources
  4. Group NMS: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801–807.
    External Resources
  5. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985;6:199–226.
  6. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C: Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823–827.
    External Resources
  7. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;ii:57–66.
  8. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13.
    External Resources
  9. Rinfret S, Abrahamowicz M, Tu J, Humphries K, Eisenberg MJ, Richard H, Austin PC, Pilote L: A population-based analysis of the class effect of beta-blockers after myocardial infarction. Am Heart J 2007;153:224–230.
    External Resources
  10. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M: The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124–130.
    External Resources
  11. Gislason GH, Abildstrom SZ, Rasmussen JN, Rasmussen S, Buch P, Gustafsson I, Friberg J, Gadsboll N, Kober L, Stender S, Madsen M, Torp-Pedersen C: Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995–2002. Scand Cardiovasc J 2005;39:42–49.
    External Resources
  12. Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, Rasmussen S, Kober L, Stender S, Madsen M, Torp-Pedersen C: Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153–1158.
    External Resources
  13. Gaist D, Andersen M, Aarup AL, Hallas J, Gram LF: Use of sumatriptan in Denmark in 1994–5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997;43:429–433.
    External Resources
  14. Gaist D, Sorensen HT, Hallas J: The Danish prescription registries. Dan Med Bull 1997;44:445–448.
    External Resources
  15. Jackevicius CA, Anderson GM, Leiter L, Tu JV: Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med 2001;161:183–188.
    External Resources
  16. Rasmussen S, Zwisler AD, Abildstrom SZ, Madsen JK, Madsen M: Hospital variation in mortality after first acute myocardial infarction in Denmark from 1995 to 2002: lower short-term and 1-year mortality in high-volume and specialized hospitals. Med Care 2005;43:970–978.
    External Resources
  17. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–1390.
    External Resources
  18. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512–1515.
    External Resources
  19. Roden DM: Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994;331:785–791.
    External Resources
  20. Delea TE, Stanford R, Hagiwara M, Edelsberg JS, Oster G: Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. Int J Cardiol 2005;99:117–124.
    External Resources
  21. Abildstrom SZ, Rasmussen S, Madsen M: Changes in hospitalization rate and mortality after acute myocardial infarction in Denmark after diagnostic criteria and methods changed. Eur Heart J 2005;26:990–995.
    External Resources
  22. Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105–116.
    External Resources
  23. Ess SM, Schneeweiss S, Szucs TD: European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21:89–103.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: December 19, 2007
Accepted: January 31, 2008
Published online: July 09, 2008
Issue release date: December 2008

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2009, Vol.112, No. 2

December 2008

Article

Recommend This
TOP